Experimental study reveals significant metabolic changes in glioblastoma treatment using lonidamine and temozolomide, suggesting a promising therapy alternative.
Motivation: To develop an alternate effective therapy for treating glioblastomas. Goal(s): To assess metabolic changes as therapeutic indices of treatment response to Lonidamine (LND)and temozolomide (TMZ) against glioblastoma (GBM). Approach: C57BL6 mice implanted with GL261 GBM cells were treated with saline or LND+TMZ. Metabolic changes were monitored using longitudinal MRS. Results: Significant reductions in lactate, tCho/NAA, Lip+Lac/tCr and mI/tCr ratios, were observed post-treatment, suggesting early indicators of treatment response. Impact: This combination therapy might be a suitable alternative for better treatment of glioblastomas.
No takes yet. Share an insight, caveat, or question.
Alrashidi et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: